If someone has run amylin analogue mechanism properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable.
Trying to work out what would count as evidence on amylin analogue mechanism, before collecting any. This is the part I usually skip and it is the part that makes the rest useful.
If two explanations predict the same observation, observing it does not help. So: what observation would separate them?
Narrowing the opening post, because the general version has more than one answer.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
Someone should write this up properly, and it should probably not be me.
The opening post put the caveat in the right place and I want to underline it.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
I would put moderate confidence on the mainstream reading of amylin analogue mechanism and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
I read post #3 twice before replying, because I had assumed the opposite.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Post #3 answers the question as asked. The question underneath it is different.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Noted, and I have changed what I was going to do on the strength of it.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
That matches what I was told, which is not the same as knowing it.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
The confident version of this sentence would be wrong, so here is the hedged one.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
I would be glad to be shown a cleaner way of putting this.
The arithmetic in post #12 is right; the assumption feeding it is the part to check.
If you are new and reading this thread for the answer to amylin analogue mechanism: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Answering the question post #10 raises rather than the one it answers.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
The mechanism is plausible, which is not the same as established.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
The answer changed when I changed how I was measuring, which was informative.
Noted, and thank you for writing it out rather than summarising it.
Following this. I have the same question and no better information than the first post.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
Coming back to post #20, because the follow-up matters more than the original answer.
Practical note on amylin analogue mechanism: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
I disagree with the framing of amylin analogue mechanism above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
Noting that the question and the thing people usually mean by it are different.
This follows post #23 rather than contradicting it.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
I am reporting what happened, not recommending it.
I had written a reply contradicting post #23 and deleted it. Here is what survived.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
One more caveat and then I will stop qualifying: the sample selected itself.
Confirming post #23 from a second method, which matters more than confirming it from a second person.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
Written quickly, so the reasoning may be tighter than the wording.
That reframing is the whole thing. The facts I already had.
Narrowing post #28, because the general version has more than one answer.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
I keep a log of this specifically because memory is unreliable about it.